Variations and implications of Irisin, FGF-23, and N-MID osteocalcin in diabetic osteoporosis patients undergoing acarbose plus sitagliptin therapy: A prospective cohort analysis.

BACKGROUND

The present study intends to explore the dynamic variations in Irisin, fibroblast growth factor 23 (FGF-23), and N-terminal propeptide of osteocalcin (N-MID) among diabetes mellitus osteoporosis (DOP) patients undergoing treatment with acarbose plus sitagliptin, as well as their ability to predict bone metabolic status and fracture risk. The ultimate objective is to identify potential biomarkers for optimizing DOP therapy.

METHODS

From January 2023 to March 2024, 124 DOP patients admitted to our hospital were administered acarbose in combination with sitagliptin. For comparison, 119 uncomplicated diabetes mellitus (DM) patients were recruited as controls. Serum levels of Irisin, FGF-23, and N-MID were tested both at baseline and post-treatment. Data on bone mineral density (BMD), bone metabolic markers, and fracture occurrences during follow-up were also collected.

RESULTS

Compared with uncomplicated DM individuals, DOP patients exhibited a rise in FGF-23 (P< 0.05) and a decrease in Irisin and N-MID (P< 0.05). Irisin + FGF-23 + N-MID combination demonstrated 87.10% sensitivity and 74.58% specificity in diagnosing DOP (AU C= 0.867). Treatment with acarbose and sitagliptin contributed to reduced FGF-23 in DOP patients, along with increased Irisin and N-MID (P< 0.05). BMD was positively influenced by irisin but negatively affected by FGF-23. Fracture prediction efficacy was markedly enhanced (AU C= 0.822) by combining the three indices, with statistical superiority over single-index analysis (P< 0.05).

CONCLUSIONS

The combined detection of Irisin, FGF-23, and N-MID enables early detection of DOP while allowing for dynamic assessment of treatment outcomes and fracture risk.